Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and lowers the price target fro...
aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in th...
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our t...
Wells Fargo analyst Derek Archila downgrades aTyr Pharma (NASDAQ:ATYR) from Overweight to Equal-Weight and lowers the price ...
RBC Capital analyst Brian Abrahams downgrades aTyr Pharma (NASDAQ:ATYR) from Outperform to Sector Perform and lowers the pri...
